Microfluidic Flow Retardation for Tagless Cancer Cell Analysis
Abstract
We developed a microfluidic device to detect surface protein expression in individual cancer cells in small cell populations without prior labeling. We used LM2 cells (kind gift of Juan Massague, Memorial Sloan-Kettering Cancer Center, NY), derived from murine lung metastases of MDA-MB-231 cells that have a unique potential to re-metastasize to lung. We selected LM2 cells for 100% sustained expression of IL-13RA2 and cells without expression. We coated the channel with an antibody to IL- 13RA2 or with BSA and directed cells over the patch by a microsyringe pump at flow rates of nanoliters per second. The transient interactions with surface ligands resulted in retardation of rolling rates in cells expressing the cognate surface protein over the antibody-coated patches and rapid, unimpeded flow on BSA or in the absence of expression of the antigen with 100% specificity. We detected and tracked cells with microscope objectives and computer tracking programs. We have achieved our objectives for the first year of the project in developing this method and are proceeding to achieve high sensitivity with single and tandem patches and maintaining 100% specificity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2011
- Accession Number
- ADA549637
Entities
People
- Robert Wieder
Organizations
- New Jersey Medical School